Chinese multiple myeloma patients at high risk benefit more from autologous stem cell transplantation

Abstract

Objective To evaluate effects of autologous stem cell transplantation (ASCT) on new diagnosed multiple myeloma (MM) patients.Methods 42 newly diagnosed MM patients who obtained partial remission (PR) or better and received ASCT were selected.With a median 34.2 months follow-up,therapeutic effects,progression-free survival (PFS) and overall survival (OS) of 42 newly diagnosed patients received ASCT were analyzed.49 patients who obtained PR or better after induction therapy but not received ASCT were selected as control.The differences of these two groups were analyzed and effects of ASCT on new diagnosed MM patients were evaluated.Results Compared with non-ASCT patients,patients received ASCT had longer OS (not reached vs 37.2 months,P =0.000).ASCT could also prolonged PFS of MM patients,but there was not significant difference (33.9 months vs 39.8 months,P =0.133).ASCT could significantly improved PFS of MM patients with DS Ⅲ stage (P =0.009) and ISS Ⅲ stage (P =0.049),however,it could improve PFS of DS Ⅰ /Ⅱ stage and ISS Ⅰ/Ⅱ] stage.ASCT could significantly improve PFS of patients obtained complete remission (CR) (P =0.016),however,it had not significant effect on patients obtained very good PR (VGPR) or PR after induction therapy.ASCT could significantly improved OS of patients aged ≤55 years old (P =0.039) and ＞ 55 years old (P =0.000).ASCT could significantly improved OS of MM patients with ISS Ⅰ /Ⅱ stage (P =0.003),ISS Ⅲ stage (P =0.012) and DS Ⅲ stage (P =0.000),however,it had not significant effect on patients with DSⅠ/ Ⅱ] stage (P =0.446).After induction therapy,ASCT could further improved OS of patients obtained CR (P =0.004) or VGPR/PR (P =0.004).Conclusion ASCT could significantly improve OS of new diagnosed MM patients and could make MM patients obtaine more benefits who are at high risk at age and stages. Key words: Multiple myeloma; Autologous stem cell transplantation; Overall survival